In the present study, the recognition of epitope variants of influenza A viruses by human CTL was investigated. To this end, human CD8 ؉ CTL clones, specific for natural variants of the HLA-B*3501-restricted epitope in the nucleoprotein (NP 418 -426 ), were generated. As determined in 51 Cr release assays and by flow cytometry with HLA-B*3501-peptide tetrameric complexes, CTL clones were found to be specific for epitopes within one subtype or cross-reactive with heterosubtypic variants of the epitope. Using eight natural variants of the epitope, positions in the 9-mer important for T cell recognition and involved in escape from CTL immunity were identified and visualized using multidimensional scaling. It was shown that positions 4 and 5 in the 9-mer epitope were important determinants of T cell specificity. The in vivo existence of CD8
C ytotoxic T lymphocytes play an important role in the control of viral infections. In influenza A virus-infected mice, CTL were shown to contribute to protective immunity against viruses of various subtypes (1) (2) (3) (4) (5) , while human CTL have been reported to reduce morbidity and virus titers in the lung (6, 7) . Recently, it was demonstrated that CTL immunity can exert selective pressure on influenza A virus CTL epitopes, further implicating a role for CTL in the control of influenza virus replication in infected individuals (8, 9) . Beside amino acid changes in the anchor residues of CTL epitopes (8) , changes in nonanchor residues were observed in an HLA-B*3501-restricted CTL epitope within the nucleoprotein (NP) 3 of influenza A virus (NP 418 -426 ) (9) . Epitope variants of influenza A (H3N2) viruses (homosubtypic variants) were found to emerge in a chronological order (9) . In addition, a variant of the epitope was identified in influenza A (H1N1) viruses, which differed from those found in A/H3N2 viruses (heterosubtypic variant). Although the majority of CTL epitopes are conserved between different subtypes (2, 10 -13), both human and murine CTL have been described that recognize a single subtype of influenza A virus (9, 10, 14 -16) . It has been shown that sequential infections with two influenza A viruses, containing different variants of the same epitope, induced CTL reactive against both epitopes, whereas infection with one influenza A virus only induced CTL reactive with the homologous peptide sequence (17, 18) . These experiments were conducted in naive mice and are difficult to extrapolate to humans. Data on the cross-reactive nature of human influenza A virus-specific CTL are limited (19) .
The observed variability in the HLA-B*3501-restricted epitope NP 418 -426 allows investigation of the cross-reactive nature of CTL obtained from humans which constitute a natural host for influenza viruses. In this study, the recognition of natural epitope variants by clonal and polyclonal T cell populations was studied. T cell recognition was studied in conventional 51 Cr release assays and also by direct visualization of T cells displaying monospecific or crossreactive TCRs using HLA-B*3501-peptide tetrameric complexes (20) .
It was found that most CTL recognize one subtype of currently circulating influenza A viruses. However, some of the CTL exhibited a broader recognition pattern and recognized homosubtypic and even heterosubtypic variants of epitope NP 418 -426 . Based on these findings obtained in vitro, the origin of these cross-reactive CTL is discussed.
Materials and Methods

Cells
PBMC from normal healthy nonvaccinated HLA-B35 ϩ blood donors (Table I), between 30 and 48 years of age, were isolated between 1999 and 2001 using Lymphoprep (Nycomed, Oslo, Norway) gradient centrifugation and cryopreserved at Ϫ135°C. HLA sero-and genotyping was performed in the laboratory for Histocompatibility and Immunogenetics at the Sanquin Bloodbank Rotterdam (The Netherlands) using a commercial typing system (GenoVision, Vienna, Austria).
Serology
Plasma samples were stored at Ϫ20°C and tested for the presence of influenza A virus (H3N2 and H1N1)-specific Abs in a hemagglutination inhibition (HAI) assay according to standard methods (21, 22) using turkey erythrocytes and four hemagglutinating units of virus. The sera were tested for Abs against 11 vaccine strains of subtype H3N2 and 6 vaccine strains of the H1N1 subtype used since 1968. Ferret sera raised against the test Ags were used as positive controls. A HAI titer of Ͼ20 against a vaccine strain used in a particular season was considered indicative of an infection with an epidemic influenza A virus of that year.
Influenza A viruses and peptides
Sucrose gradient purified influenza A viruses were used for the infection of PBMC and cells of B lymphoblastoid cell lines (BLCL). Resvir-9 is a reassortant virus between A/Puerto Rico/8/34 (H1N1) and A/Nanchang/ 933/95 (H3N2) containing the NP, hemagglutinin, and neuraminidase of A/Nanchang/933/95 with the LPFEKSTVM variant of the NP 418 -426 epitope (designated NP ESV ), which was first identified in 1980 (Table II) . A second virus, A/Victoria/3/75 (H3N2) containing the LPFDKSTIM variant of the NP 418 -426 epitope (designated NP DSI ), introduced in 1972, was also used. As prototype of currently circulating H1N1 viruses in The Netherlands, we used A/Netherlands/306/00. This virus contains the LPFDKT TIM variant of the NP 418 -426 epitope (designated NP DTI , Table II ). The infectious virus titers of the virus preparations were determined in cell culture using Madin-Darby canine kidney cells as indicator cells, as described previously (23) . All peptide analogues of epitope NP 418 -426 found in human influenza A viruses were manufactured, HPLC purified, and analyzed by mass spectrometry (Eurogentec, Seraing, Belgium). Influenza A virus NP sequence information was obtained from the Influenza Sequence Database (Los Alamos National Laboratories, Los Alamos, NM) (24) . Peptides were dissolved in DMSO at 5.0 mg/ml, diluted to 100 M in RPMI 1640 (Invitrogen, Breda, The Netherlands), and stored at Ϫ20°C until use.
In vitro stimulation of PBMC with influenza A virus
Stimulation of PBMC with influenza A virus was performed as previously described (25) . The cells were resuspended at 10 6 cells/ml in RPMI 1640 medium supplemented with 10% FCS, 2 mM glutamine, 100 g/ml streptomycin, and 100 IU/ml penicillin (R10F). Following a 1-h infection at 37°C with Resvir-9, A/Victoria/3/75 or A/Netherlands/306/00 at a multiplicity of infection of three, the cells were washed once and resuspended in RPMI 1640 medium supplemented with 10% human AB serum, 2 mM glutamine, 100 g/ml streptomycin, 100 IU/ml penicillin, and 20 M 2-ME (R10H) and added to uninfected PBMC at a ratio of 1:1 in a 25-cm 2 culture flask. The PBMC were incubated for 2 days before rIL-2 (final concentration 50 U/ml; Chiron, Amsterdam, The Netherlands) was added. Subsequently, the cells were incubated for 6 days at 37°C and used as effector cells in a 51 Cr release assay or stained with fluorochrome-labeled HLA-B*3501-peptide tetrameric complexes (see below).
Generation of NP 418 -426 -specific CD8
ϩ T cell clones CTL clones were generated by limiting dilution assay (8) 
Screening of virus or epitope-specific T cell clones by ELISPOT assay
Approximately 10 4 cells of a T cell clone were added to an equal number of HLA-B*3501-positive BLCL cells that were infected with influenza A virus, uninfected, or loaded with one of the NP 418 -426 peptide variants in 150 l of R10F in a 96-well V-bottom plate. Following a 1-min centrifugation at 140 ϫ g, the plate was incubated for 2 h at 37°C before the cells were transferred to a 96-well Silent Screen Plate (Nalge Nunc, Rochester, NY) coated with anti-human IFN-␥ mAb (Mabtech, Nacka, Sweden). After 4 h at 37°C, the plates were washed and developed according to the manufacturer's recommendations. T cell clones that produced IFN-␥ in the presence of peptide-loaded BLCL or virus-infected BLCL cells and failed to produce IFN-␥ after stimulation with negative control BLCL cells were selected for further investigation. 51 Cr release assay BLCL were established as previously described (26) and used as target cells in 51 Cr release assays. Cells of an HLA-B*3501-positive BLCL were infected with Resvir-9, A/Victoria/3/75, or A/Netherlands/306/00 at a multiplicity of infection of three in RPMI 1640 medium containing 0.1% BSA, 2 mM glutamine, 100 g/ml streptomycin, and 100 IU/ml penicillin (R0.1B). After 1 h at 37°C, the cells were washed once in R10F and cultured in R10F for 16 h at 37°C. To test the ability of CTL clones to recognize synthetic peptides, 10 6 cells of a BLCL were loaded with 5 M of different NP 418 -426 epitope variants for 16 h at 37°C in R10F. Radioactively labeling of peptide-loaded and virus-infected BLCL cells was done with Na 2 51 CrO 4 for 1 h at 37°C, after which the cells were washed three times with R10F and used as target cells in a 51 Cr release assay. As a measure of functional avidity of CTL clones (27) , the minimal peptide concentration was determined for which 50% of the target cells were killed (epitope concentration (EC 50 )). 51 Cr-labeled HLA-B*3501-positive BLCL cells were distributed in 96-well V-bottom plates. Next, the cells were subsequently incubated with 10-fold serial dilutions of peptide analogues of different NP 418 -426 epitope variants in R10F for 1 h at 37°C, washed once in R10F, and used as target cells. 51 Cr release assays were performed as described previously (25) . T cell clones were added to 5 ϫ 10 3 51 Cr-labeled target cells at different E:T cell ratios. Following a 4-h incubation at 37°C, the culture supernatants were harvested (Skatron Instruments, Sterling, VA) and radioactivity was measured by gamma counting. The percentage of specific lysis was calculated with the following formula: ((experimental release Ϫ spontaneous release)/ (maximum release Ϫ spontaneous release)] ϫ 100. The data are presented as the average percentage of specific lysis of at least three wells.
Preparation of target cells for
Cr release assay
Flow cytometry and tetramer staining
HLA-B*3501 molecules were complexed with four different HLA-B*3501-restricted NP 418 -426 epitope variants within the NP of influenza A 
Multidimensional scaling (MDS)
An "antigenic map" based on the reactivity of the CTL clones against the variant peptides was constructed from the EC 50 values of the variant NP 418 -426 peptides for each CTL clone (29, 30) . The map-making technique is a combination of metric (31) and nonmetric (32) MDS. The distance between two grids in the map corresponded to a 10-fold dilution of the peptide, starting at an EC 50 value of 0.001 nM (the most parsimonious choice for these data). The distance between a peptide and a CTL clone or two peptides is a measure for respectively the avidity between peptides and a CTL clone or antigenic dissimilarity between variant peptides. The clones and the peptides are positioned to minimize the sum of the squared errors between the target distances and the achieved map distances. The average error between target and achieved distances is 0.37 10-fold dilutions (SD ϭ 0.45), indicating a good fit in two dimensions.
Results
Validation of staining of NP 418 -426 -specific CTL with differentially labeled tetramers
In addition to six previously described CTL clones (Ref . 9 and  Table III) , obtained after stimulation with two NP 418 -426 epitope variants associated with the H3N2 subtype of influenza A viruses (NP ESV and NP DSI ), three additional CTL clones were generated against the currently circulating NP 418 -426 epitope variant of H1N1 viruses (NP DTI ). The original stimulation protocol and origin of PBMC is given for each CTL clone (Table III) . All CTL clones exhibited lytic activity against at least one of the viruses (Table IV) (Fig. 1) . Finally, clone 3180 bound all four tetramers containing different homo-and heterosubtypic variants of the epitope confirming the cross-reactive nature of this T cell clone. Overall, the ability of the CTL clones to bind tetramers with different peptides correlated well with their ability to kill virus-infected target cells.
Antigenic properties of NP 418 -426 epitope variants
The antigenic properties of the epitope variants were studied by measuring the functional avidity of the respective T cell clones as EC 50 value for each of the peptides (Table V ). An example of such an analysis is shown for CTL clone 3180 (Fig. 2) . Using the EC 50 values, an antigenic map was constructed by MDS. Using this mathematical procedure, the antigenic dissimilarity of the peptides and the avidity of NP 418 -426 -specific CTL clones for these peptides is visualized by the relative positioning of the peptides and T cell clones in a plot (Fig. 3) . The glutamic acid (E) to an aspartic acid (D) substitution at P4 or vice versa reduced functional avidity of six CTL clones (15.9, F10, G2, 2384, 5017, and C4), but not of clone 3180, D1, and C10 (Table V) . The large distance in the MDS plot between peptides containing an E and those containing a D at P4 exemplified their antigenic dissimilarity. The lysine (K) to arginine (R) substitution at P5 reduced the functional avidity of CTL clones 2384, 5017, and 3180. As a result, an R at P5 outplaced peptide LPFDRTTIM, confirming the importance of a K at this position for recognition by these NP DTI -specific CTL clones (Fig.  3) . CTL clone C4 tolerated both the S3 T and the S3 P substitutions at P6. CTL clones 2384, 5017, and 3180 all tolerated the T3 S substitution, but the T3 P substitution reduced the avidity of clones 2384 and 5017 more than 10,000-fold and that of clone 3180 300-fold. The S3 T substitution at P6 significantly reduced the functional avidity of four of the NP ESV -specific CTL clones (D1, C10, 15.9, and F10) when the reactivity to the LPFEKSTIM was compared with that to LPFEKTTIM. CTL clones D1, C10, 15.9, G2, and C4 tolerated a valine (V) to isoleucine (I) substitution at P8, while the EC 50 value for this variant epitope increased by a factor of 260 in CTL clone F10. In the antigenic map (Fig. 3) , the NP ESV -specific T cell clones (D1, C10, 15.9, F10, and G2) were positioned in close proximity to the LPFEKSTVM peptide against which they were raised in vitro. Likewise, clones 2384, 5017, and C4 were positioned in proximity of their homologous peptides, although C4 was situated closer to the heterologous peptide LPFDKTTIM and clones 2384 and 5017 to the heterologous peptide LPFDKSTIM. Finally, clone 3180 was positioned in the middle of the plot, close to the H1N1 peptide and the H3N2 peptides from 1972 and 1980, confirming its ability to recognize hetero-and homosubtypic variants of the NP 418 -426 epitope.
Staining of influenza A virus-stimulated PBMC with HLA-B*3501-peptide tetramers that contain different NP 418 -426 variants
The specificity of NP 418 -426 tetramer staining was confirmed with well-defined CTL clones and this technology was then used to evaluate the specificity of NP 418 -426 -specific human polyclonal CTL responses using PBMC stimulated with influenza A virus. Following stimulation of PBMC of five HLA-B35 ϩ donors with Resvir-9, a H3N2 virus containing the NP ESV epitope, the percentage of NP ESV -specific cells ranged from 1.1 to 18.5% of the CD8 ϩ cells ( Fig. 4a and data not shown). In the same PBMC cultures, the percentage of NP DTI -, NP DSI -, and NP DPI -specific cells was also determined using HLA-B*3501-peptide tetrameric complexes containing the respective peptides. In the in vitro expanded PBMC of donor 1 small numbers of NP DTI and NP ESV double-reactive CD8 ϩ cells were observed (0.4%), demonstrating the presence of heterosubtypic reactive CD8 ϩ cells (Fig. 4a) . In the PBMC of the remaining four donors, no NP DTI -specific cells were detected after stimulation with Resvir-9. The ability to recognize homosubtypic variants of the NP 418 -426 epitope following stimulation with a virus containing the NP ESV variant peptide (Resvir-9) was variable between donors. In donors 1 and 2 a fraction of the NP ESV -specific cells also bound to NP DSI tetramers (Fig. 4a) , while in donors 3-5 the NP ESV -specific cells did not bind to NP DSI tetramers (Fig. 4a  and data not shown) . Finally, in vitro expanded NP ESV -specific CD8 ϩ cells did not bind to the NP DPI tetramer (Fig. 4a) . Similar experiments were performed with PBMC following stimulation with influenza viruses A/Victoria/3/75 (H3N2, NP DSI ) or A/Netherlands/306/00 (H1N1, NP DTI ). Of each of the five donors tested, 0.4 -4.5% of the CD8 ϩ cells that were expanded after stimulation with influenza virus A/Victoria/3/75 bound to the homologous NP-DSI tetramers. In some donors, a large fraction of the NP DSI -specific cells also bound to the NP DTI tetramers (donors 1, 3, and 4, Fig. 4b and data not shown), indicating a high degree of crossreactivity between these epitopes. The NP DSI -specific cells from donor 2 however, cross-reacted with the NP ESV tetramer and not with the NP DTI tetramer, confirming the existence of homosubtypic cross-reactive CTL in this donor. Upon stimulation with influenza virus A/Netherlands/306/00, NP DTI -specific CD8 ϩ cells were detected in some PBMC cultures (range, 0.0 -6.2%, Fig. 4c) . Most of the NP DTI -specific CD8 ϩ cells also bound the NP DSI tetramers (donors 1, 3, and 4, Fig. 4c and data not shown) . In addition, a portion of the NP DTI -specific cells from donor 1 crossreacted with NP ESV tetramers (Fig. 4c) , confirming the existence of these cells following stimulation with Resvir-9 virus. Finally, only in donor 3 some NP DTI -specific cells in the PBMC cultures stimulated with A/Netherlands/306/00 also bound to the NP DPI tetramers (Fig. 4c) . Thus, tetramer staining provided evidence for the existence of CTL cross-reactive with current H3N2 (NP ESV ) and H1N1 (NP DTI ) viruses in one donor, whereas in the other four donors only influenza A virus subtype-specific cells were demonstrated or cells cross-reactive with previous H3N2 (NP DSI ) and current H1N1 (NP DTI ) viruses.
Influenza A virus-specific Ab titers
To correlate the NP 418 -426 -specific CTL response in the PBMC of donors to the history of influenza A virus infections, serum HAI titers specific for A/H1N1 and A/H3N2 viruses were determined.
Serum Abs were detected in donor 1 against the 1978 vaccine strain (H1N1), which cross-reacted with later vaccine strains, and the 1991 vaccine strain. Abs specific for H3N2 viruses were observed against A/Hong Kong/1/68 (NP DPI ) and the 1995 vaccine strain (NP ESV ). These findings indicate that donor 1 was exposed to influenza A viruses of the H1N1 subtype around 1978 and 1991 and to the H3N2 viruses around 1968 and 1995 (Fig. 4d) . In donor 2, Abs specific for 1968, 1977, and 1995 vaccine strains of the H3N2 subtype were readily detected (Fig. 4d) . These findings suggest that this donor has experienced multiple exposures to influenza A viruses of the H3N2 subtype but not to those of the H1N1 subtype. Donor 3 had serum Abs against the 1968 and 1995 strain of the H3N2 subtype (Fig. 4d ) and low levels of Abs against the 1978 and 1983 strains of the H1N1 subtype. Donor 4 was found to have serum Abs to viruses of the A/H3N2 (1977, 1979, 1982, 1987, and 1995) and the A/H1N1 subtype (1978, 1983, and 1996) , whereas in donor 5 solely Abs against viruses of the H3N2 subtype from 1977, 1979, 1995, and 1998 were detected (data not shown).
Discussion
In the present study, the recognition of natural variants of an HLA-B*3501-restricted CTL epitope within the NP of influenza A viruses by human clonal and polyclonal CTL populations was investigated. Using classical 51 Cr release assays and direct visualization of specific T cells with tetramers, CTL were identified that were cross-reactive with homo-and heterosubtypic variants of the epitope. The use of CTL clones specific for the respective epitope variants allowed the identification of residues involved in TCR recognition. Based on the finding that cross-reactive CTL were found at low frequencies in PBMC stimulated with influenza virus, we hypothesize that in response to influenza virus infections, HLA-B*3501-positive individuals develop a CTL response against the homologous epitope variant of which a small proportion may be cross-reactive with other variants. These cross-reactive cells may then be further expanded upon a subsequent infection with viruses carrying a heterologous variant epitope. It was assumed that the study subjects were infected in the past with a homogeneous virus population with regard to the epitope NP 418 -426 , based on epidemiological data on the circulation of these variants (24) .
The results obtained in 51 Cr release assays with virus-infected target cells and direct visualization with labeled tetramers correlated well, confirming the specificity of these procedures and the antigenic dissimilarity of the epitopes. Using serial dilutions of the peptides, the avidity of the CTL clones for the peptides was determined in 51 Cr release assays and the effect of the amino acid substitutions was assessed. In vitro three T cell clones were established after stimulation with peptide NP DTI (5017, 2384, and 3180) and one after stimulation with NP DSI (C4). Although these clones had high avidity for these peptides, it is not clear which variant of the epitope had primed these CTL in vivo. As can be judged from (Table  V) . The CTL clones are depicted by squares while circles represent the variant peptides. The large circles contain the CTL clones and the NP 418 -426 epitope variant used for in vitro stimulation of these clones. The distance between two grids corresponds to a 10-fold dilution in EC 50 value. For example, the EC 50 value for clone 15.9 with peptide LPFEKSTIM is 0.1 nM; this is two 10-fold dilutions from the assumed baseline titer of 0.001 nM, thus the "target" distance from clone 15.9 to peptide LPFEK STIM when constructing the map was 2 U.
the EC 50 values (Table V) and the MDS plot (Fig. 3) , some clones exhibited the highest avidity for a heterologous peptide. For example, clone C4 may have been directed to NP DPI and clone 2384 to NP DSI . In contrast, T cell clones raised in vitro to peptide NP ESV all showed the highest avidity to this peptide, suggesting that indeed it was the homologous peptide responsible for the activation of these cells in vivo. MDS proved to be a useful aide in the interpretation of EC 50 values and allowed the direct visualization of recognition patterns of the respective CTL clones and the antigenic differences between epitopes.
The NP 418 -426 epitope was found to vary in influenza viruses isolated during the past 70 years at positions 4, 5, 6, and 8 of the 9-mer epitope. All peptides retained the anchor residues at positions 2 and 9, indicating that they bind to HLA-B*3501 with equal affinity, as has been demonstrated previously in an HLA peptidebinding assay (9) . Substitutions at P4 and P5 were found to have the largest effect on recognition by specific T cells as can be judged from the EC 50 values and therefore the antigenic distance in the MDS plot. The D 421 E substitution in 1980 allowed the virus to escape from NP DSI -specific CTL (9) . These findings coincide with data obtained with dengue virus-specific CTL, confirming the importance of position 4 for the recognition of an HLA-B*3501-restricted epitope (33) . Although a mutation at P4 had a major impact on TCR recognition, CTL do exist (3180) that recognize peptides containing either an E or a D at position 4. These CTL may have been selected for by repeated infections with different influenza A viruses containing different variants of the epitope. The K 422 R substitution also had a dramatic effect on the recognition of the epitope. However the R at amino acid position 422 on the NP is rare and has only been found in influenza A viruses isolated in 1933 and 1934 and in several human isolates of avian origin. Substitutions at P6 and P8 had relatively little impact on TCR recognition, although for most NP ESV -specific T cell clones the T3 S substitution at P6 reduced the TCR avidity for the ϩ blood donor HAI assays were performed on plasma obtained from donors 1-5 using 6 different H1N1 vaccine strains (E) and 11 different H3N2 vaccine strains (F) used since 1968. The HAI titers specific for each vaccine strain are depicted for donors 1-3 against the years in which the vaccine strains were isolated.
epitope. In contrast to NP 418 -426 -specific CTL, CTL specific for an HLA-B*3501-restricted epitope of dengue virus (NS 500 -508 ) tolerated an amino acid substitution at position 8 poorly (33) .
Upon stimulation of PBMC with different influenza A viruses, various recognition patterns were observed that correlated partially with the history of infections of the respective donors (see below). In three donors (donors 1, 3, and 4), CTL expanded after stimulation with influenza virus A/Netherlands/306/00 (of the H1N1 subtype containing NP DTI ) were cross-reactive with the NP DSI variant present in influenza viruses of the H3N2 subtype, circulating between 1972 and 1980 and vice versa. Thus, also stimulation with A/Victoria/3/75 (H3N2) led to the expansion of NP DSI -specific cells cross-reactive with NP DTI . This finding resembles the cross-reactivity observed with CTL specific for epitopes in HIV-1, dengue virus, and SIV (33) (34) (35) . HIV-1-specific CTL could recognize variants of epitopes present in different clades of this virus. An important difference between influenza virus and HIV-1 infections is that individuals usually are not infected with HIV from different clades whereas for influenza, repeated infections with variant viruses of distinct or the same subtype is very common. For that reason, repeated infections with variant viruses may select for cross-reactive CTL from the pool of NP 418 -426 -specific CTL induced during the primary infection. To correlate the presence of cross-reactive CTL with the history of influenza A virus infections of the respective donors, serology was performed. Because of the relative insensitivity of the HAI assay and waning Ab titers over time, failure to detect serum Abs against a certain virus may not be conclusive regarding the lack of exposure to this virus in the past. However, a positive result in this assay was considered indicative for a history of infection. Donor 1 was infected with an influenza A virus of the H1N1 subtype and subsequently with an H3N2 virus. This is in agreement with the observation in this donor of NP DTI -and NP ESV -specific cells. A small proportion of these cells cross-reacted with NP ESV and NP DTI . The strong staining with the NP ESV tetramers (NP ESV high ) and the relatively weak staining with the NP DTI tetramer (NP DTI low ) of these double-reactive CTL detectable after stimulation of PBMC with Resvir-9 and A/Netherlands/306/00 suggests that these NP ESV high NP DTI low CTL have a stronger avidity for the NP ESV variant of the epitope. However, since the tetramers were used at nonsaturating concentrations it is impossible to draw firm conclusions regarding the avidity of the CD8 ϩ cells for the respective tetramers. Donors 2 and 5 were found to be exposed to viruses of the H3N2 subtype circulating in 1977 and 1995 and not to H1N1 viruses. As a result, NP ESV monospecific CTL were found in both donors and not T cells reactive with the NP DTI (H1N1) variant of the epitope. In addition, homosubtypic cross-reactive CTL were found in donor 2. In donor 4, the serology correlated with the presence of NP ESV -and NP DTI -specific cells, although cross-reactive cells were not observed in this donor. A similar reaction pattern was observed in donor 3, although H1N1-specific Ab titers were very low. The absence of heterosubtypic cross-reactive CTL may be explained by the long period between infection with an H1N1 virus and an H3N2 virus. Thus, in two of five donors tested, there was evidence for the existence of T cells cross-reactive with homo-and heterosubtypic variants of the NP 418 -426 epitope. The heterogeneity in the NP 418 -426 -specific responses in these donors of similar age can be the result of differences in history of infection as well as many other factors influencing the CTL response in these donors.
In mice it has been demonstrated ex vivo (17) and in vitro (18) that consecutive infections with influenza viruses containing different variants of the same epitope (NP 366 -374 ) resulted in the expansion of CTL able to recognize both variants of the epitope, whereas infection with the same virus resulted in the induction of monospecific cells. This expansion of cross-reactive CTL may even take place after consecutive infections with unrelated viruses as has also been observed in mice (36, 37) . We hypothesize that also in humans cross-reactive CTL can be selected for against variable epitopes by multiple infections with influenza viruses carrying variant epitopes (apart from true cross-reactive responses against conserved epitopes).
The percentage of heterosubtypic cross-reactive T cells specific for the NP 418 -426 epitope is relatively small in the subjects compared with those observed in vivo in mice. In some of the donors, there was no evidence for exposure to both subtypes, explaining the absence of cross-reactive CTL. The timing of the infections may be crucial as the frequency of cross-reactive CTL in the pool of memory cells may have declined to undetectable levels, unable to dominate the response to the variant epitope.
We conclude that upon influenza virus infections a small proportion of the NP 418 -426 -specific CTL can cross-react with variants of the epitope. Apparently the flexibility of the TCR of this subset of CTL allows the recognition of naturally occurring variants of the epitope that may be escape mutants selected for by CTL-mediated immune pressure. This subset of cross-reactive CTL may increase after repeated infections with heterologous viruses and may contribute to protective immunity against arising mutant viruses.
